• Publications
  • Influence
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
Myeloproliferative disorders are clonal haematopoietic stem cell malignancies characterized by independency or hypersensitivity of haematopoietic progenitors to numerous cytokines. The molecularExpand
  • 2,047
  • 98
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
Myeloproliferative disorders are clonal haematopoietic stem cell malignancies characterized by independency or hypersensitivity of haematopoietic progenitors to numerous cytokines. The molecularExpand
  • 937
  • 71
Mutation in TET2 in myeloid cancers.
BACKGROUND The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. The mechanisms underlying these disorders are not well defined.Expand
  • 1,028
  • 45
Prognostic score including gene mutations in chronic myelomonocytic leukemia.
PURPOSE Several prognostic scoring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some gene mutations-including ASXL1-have been associated with poorExpand
  • 369
  • 40
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.
Loss-of-function mutations affecting one or both copies of the Ten-Eleven-translocation (TET)2 gene have been described in various human myeloid malignancies. We report that inactivation of Tet2 inExpand
  • 679
  • 29
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin (CALR), andExpand
  • 209
  • 27
  • PDF
Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.
To update oncologists on pathogenesis, contemporary diagnosis, risk stratification, and treatment strategies in BCR-ABL1-negative myeloproliferative neoplasms, including polycythemia vera (PV),Expand
  • 283
  • 24
  • PDF
New mutations and pathogenesis of myeloproliferative neoplasms.
Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by excessive production of mature blood cells. In the majority of classic MPN--polycythemia vera, essential thrombocythemia, andExpand
  • 368
  • 21
  • PDF
Specific involvement of caspases in the differentiation of monocytes into macrophages.
Caspases are cysteine proteases involved in apoptosis and cytokine maturation. In erythroblasts, keratinocytes, and lens epithelial cells undergoing differentiation, enucleation has been regarded asExpand
  • 327
  • 21
  • PDF
Mutations of ASXL1 gene in myeloproliferative neoplasms
measure epoxomicin uptake we utilized another P-gP substrate to determine if drug efflux is altered in KMS11R cells. Doxorubicin is an established substrate for P-gP and it can be easily measured inExpand
  • 294
  • 19